Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease is a research paper published in EBioMedicine (2021). On theSindex it has a DataRank of 1.2. It has been cited 58 times, with 36 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.612
From this paper's citation signal
Citation Network Contribution
0.544
From 31 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 36 citers.
National Institutes of Health
Grant: 2P20GM103427
NINDS NIH HHS
Grant: R01 NS034239
NIGMS NIH HHS
Grant: P20 GM103427
NIMH NIH HHS
Grant: R01 MH115860
National Institutes of Health
Grant: 3P20GM103427-23S2
Nebraska Research Network in Functional Genomics
National Institutes of Health
Grant: 5R01NS034239-26
Neuroprotective Immunity and HIV Dementia
National Institute of Neurological Disorders and Stroke
University of Nebraska Medical Center
FWCI
5.00
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice
Additional file 1 of Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice
Additional file 1 of An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Additional file 1 of An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Additional file 2 of An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Additional file 2 of An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Additional file 1 of Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
Additional file 2 of Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
Additional file 2 of Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
Additional file 1 of Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice